Allergic rhinitis decisions — 2025

The Board denied service connection for skin cancer of the head area, chronic sinusitis, and remanded claims for chronic rhinitis, chronic bronchitis, and emphysema.

The Veteran was granted a 50 percent rating for chronic post-traumatic headaches and a 10 percent rating for allergic rhinitis from July 29, 2014, to April 29, 2016. The claim for a higher rating for allergic rhinitis was denied.

The Board granted service connection for hypertension and an earlier effective date for allergic rhinitis, but denied service connection for sinusitis and an initial rating above 10 percent for allergic rhinitis.

The Board remands the claims for service connection for various conditions due to the Veteran's participation in a toxic exposure risk activity during his service in Afghanistan, as required by the Sergeant First Class Heath Robinson Honoring our Promise to Address Comprehensive Toxics Act of 2022 (PACT Act).

The Board denied the Veteran's claim for an initial compensable rating for service-connected chronic allergic rhinitis as the evidence did not support a finding of greater than 50 percent obstruction of the nasal passage on both sides, complete obstruction of either nasal passage, or nasal polyps.

The Board granted an earlier effective date of July 30, 2023 for the increased rating of allergic rhinitis and denied it for the skin disability and facial scars.

The Board denied a compensable evaluation for allergic rhinitis as the Veteran's condition did not meet the criteria for a 10% or higher rating.

The Board granted service connection for chronic fatigue syndrome, allergic rhinitis, and migraine headaches but denied service connection for bilateral hearing loss.

The Board denied service connection for chronic fatigue syndrome, denied increased ratings for irritable bowel syndrome with GERD and allergic rhinitis, and remanded claims for increased ratings for a low back disability and right lower extremity lumbar radiculopathy.

The Board granted readjudication of the claims for service connection for rhinitis, sinusitis, and pulmonary fibrosis due to new evidence being submitted after the initial denial.

The Board remands the claims for service connection for sinusitis and/or rhinitis, as well as tinea pedis, to correct duty to assist errors.

The Board remands the claim for an adequate VA examination to determine the current severity of the service-connected rhinitis, considering the ameliorative effects of any medication taken.

The Board granted service connection for allergic rhinitis and remanded the claims for residuals of a traumatic brain injury (TBI) and asthma.

The Board granted an effective date of August 10, 2022, for the award of service connection for sinusitis and rhinitis due to the Veteran's claims being filed within one year of the PACT Act's enactment. The dyspnea with exertion claim was denied.

The Board remands the claims for a compensable rating for non-allergic rhinitis and service connection for COPD, sinusitis, and sleep apnea due to a pre-decisional duty to assist error.

The appeal concerning service connection for a rib fracture was dismissed due to the Veteran not timely filing a VA Form 10182 with the July 2022 rating decision appealed herein. The other claims were remanded for further development.

The Board granted an effective date of October 26, 2022, for the award of a 50 percent rating for chronic sinusitis and a 40 percent rating for lumbosacral strain with degenerative disc disease (DDD), but denied an earlier effective date for allergic rhinitis.

The Veteran's appeal for an earlier effective date for the award of a 30 percent rating for allergic rhinitis was granted, while the claims for a higher rating for tinnitus and service connection for sleep disturbances were denied.

The Board granted service connection for rhinitis and sinusitis under the PACT Act, effective August 10, 2022. The claims for diabetes mellitus, type II, and direct service connection for rhinitis and sinusitis were remanded.

The Board granted service connection for skin dermatitis but denied an initial compensable rating for allergic rhinitis.